Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways.
The sGC-cGMP signaling pathway evokes vascular smooth muscle relaxation, whether this pathway mediates airway smooth muscle (ASM) relaxation remains controversial. We posit that sGC activators are equi-effective as beta agonists in reversing contractile agonist-induced ASM shortening. To provide clarity, we tested the efficacy of the sGC stimulator and activator drugs, BAY 41-2272 and BAY 60-2270 respectively, in reversing bronchoconstriction of human small airways using human precision cut lung slices (hPCLS). Both BAY drugs reversed carbachol-induced bronchoconstriction to comparable maximal levels as formoterol. Moreover, the sGC drugs remained effective bronchodilators despite formoterol-induced desensitization of the airways. Analysis of the hPCLS following their activation by sGC or β2AR agonist showed distinct cyclic nucleotide accumulation in the hPCLS. Collectively these data suggest that cAMP and cGMP pathways are equi-effective for reversing carbachol-induced bronchoconstriction in human airway via separate and distinct second messenger pathways. This should open the door for future studies to test whether sGC-targeted drugs alone or in combination can serve as effective bronchodilators in asthma and COPD.